vs
Side-by-side financial comparison of Goosehead Insurance, Inc. (GSHD) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
Goosehead Insurance, Inc. is the larger business by last-quarter revenue ($93.1M vs $86.8M, roughly 1.1× IOVANCE BIOTHERAPEUTICS, INC.). On growth, Goosehead Insurance, Inc. posted the faster year-over-year revenue change (23.1% vs 17.7%). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 9.2%).
Goosehead Insurance is a U.S.-based personal lines insurance agency that offers a wide range of coverage products including auto, home, renters, flood, and specialty insurance. It partners with hundreds of insurance carriers to provide clients with tailored, cost-effective coverage options, operating via corporate locations and a national franchise network for independent agents.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
GSHD vs IOVA — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $93.1M | $86.8M |
| Net Profit | $8.0M | — |
| Gross Margin | — | 67.4% |
| Operating Margin | 16.1% | -84.7% |
| Net Margin | 8.6% | — |
| Revenue YoY | 23.1% | 17.7% |
| Net Profit YoY | 204.0% | — |
| EPS (diluted) | $0.19 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $93.1M | — | ||
| Q4 25 | $105.3M | $86.8M | ||
| Q3 25 | $90.4M | $67.5M | ||
| Q2 25 | $94.0M | $60.0M | ||
| Q1 25 | $75.6M | $49.3M | ||
| Q4 24 | $93.9M | $73.7M | ||
| Q3 24 | $78.0M | $58.6M | ||
| Q2 24 | $78.1M | $31.1M |
| Q1 26 | $8.0M | — | ||
| Q4 25 | $12.4M | — | ||
| Q3 25 | $7.9M | $-91.3M | ||
| Q2 25 | $5.2M | $-111.7M | ||
| Q1 25 | $2.3M | $-116.2M | ||
| Q4 24 | $14.9M | — | ||
| Q3 24 | $7.6M | $-83.5M | ||
| Q2 24 | $6.2M | $-97.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | 67.4% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | — | 5.5% | ||
| Q1 25 | — | -0.8% | ||
| Q4 24 | — | 68.7% | ||
| Q3 24 | — | 46.2% | ||
| Q2 24 | — | -0.8% |
| Q1 26 | 16.1% | — | ||
| Q4 25 | 29.4% | -84.7% | ||
| Q3 25 | 23.5% | -140.7% | ||
| Q2 25 | 16.7% | -189.8% | ||
| Q1 25 | 8.8% | -245.8% | ||
| Q4 24 | 29.7% | -117.5% | ||
| Q3 24 | 21.1% | -152.1% | ||
| Q2 24 | 19.7% | -327.6% |
| Q1 26 | 8.6% | — | ||
| Q4 25 | 11.8% | — | ||
| Q3 25 | 8.7% | -135.3% | ||
| Q2 25 | 5.5% | -186.2% | ||
| Q1 25 | 3.1% | -235.5% | ||
| Q4 24 | 15.8% | — | ||
| Q3 24 | 9.7% | -142.7% | ||
| Q2 24 | 7.9% | -312.2% |
| Q1 26 | $0.19 | — | ||
| Q4 25 | $0.48 | — | ||
| Q3 25 | $0.29 | — | ||
| Q2 25 | $0.18 | $-0.33 | ||
| Q1 25 | $0.09 | $-0.36 | ||
| Q4 24 | $0.58 | $-0.24 | ||
| Q3 24 | $0.29 | $-0.28 | ||
| Q2 24 | $0.24 | $-0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $25.7M | $297.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-121.3M | $698.6M |
| Total Assets | $392.8M | $913.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $25.7M | — | ||
| Q4 25 | $34.4M | $297.0M | ||
| Q3 25 | $51.6M | $300.8M | ||
| Q2 25 | $92.4M | $301.2M | ||
| Q1 25 | $70.2M | $359.7M | ||
| Q4 24 | $54.3M | $323.8M | ||
| Q3 24 | $47.5M | $397.5M | ||
| Q2 24 | $23.6M | $412.5M |
| Q1 26 | — | — | ||
| Q4 25 | $289.5M | — | ||
| Q3 25 | $290.0M | — | ||
| Q2 25 | $289.8M | — | ||
| Q1 25 | $290.3M | — | ||
| Q4 24 | $82.3M | — | ||
| Q3 24 | $84.6M | — | ||
| Q2 24 | $87.0M | — |
| Q1 26 | $-121.3M | — | ||
| Q4 25 | $-95.5M | $698.6M | ||
| Q3 25 | $-105.0M | $702.3M | ||
| Q2 25 | $-78.6M | $698.5M | ||
| Q1 25 | $-88.5M | $767.9M | ||
| Q4 24 | $43.9M | $710.4M | ||
| Q3 24 | $58.3M | $773.5M | ||
| Q2 24 | $39.8M | $768.5M |
| Q1 26 | $392.8M | — | ||
| Q4 25 | $414.9M | $913.2M | ||
| Q3 25 | $403.6M | $904.9M | ||
| Q2 25 | $436.6M | $907.4M | ||
| Q1 25 | $412.6M | $966.7M | ||
| Q4 24 | $397.7M | $910.4M | ||
| Q3 24 | $358.1M | $991.1M | ||
| Q2 24 | $338.2M | $964.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.87× | — | ||
| Q3 24 | 1.45× | — | ||
| Q2 24 | 2.19× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-52.6M |
| Free Cash FlowOCF − Capex | — | $-61.9M |
| FCF MarginFCF / Revenue | — | -71.3% |
| Capex IntensityCapex / Revenue | — | 10.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $91.8M | $-52.6M | ||
| Q3 25 | $24.2M | $-78.7M | ||
| Q2 25 | $28.9M | $-67.4M | ||
| Q1 25 | $15.5M | $-103.7M | ||
| Q4 24 | $71.5M | $-73.3M | ||
| Q3 24 | $28.1M | $-59.0M | ||
| Q2 24 | $18.9M | $-98.4M |
| Q1 26 | — | — | ||
| Q4 25 | $86.1M | $-61.9M | ||
| Q3 25 | $23.7M | $-89.5M | ||
| Q2 25 | $27.2M | $-74.9M | ||
| Q1 25 | $14.9M | $-109.9M | ||
| Q4 24 | $70.6M | $-77.5M | ||
| Q3 24 | $28.0M | $-61.3M | ||
| Q2 24 | $18.6M | $-98.9M |
| Q1 26 | — | — | ||
| Q4 25 | 81.8% | -71.3% | ||
| Q3 25 | 26.2% | -132.7% | ||
| Q2 25 | 28.9% | -124.9% | ||
| Q1 25 | 19.7% | -222.8% | ||
| Q4 24 | 75.1% | -105.1% | ||
| Q3 24 | 35.9% | -104.6% | ||
| Q2 24 | 23.9% | -317.9% |
| Q1 26 | — | — | ||
| Q4 25 | 5.4% | 10.7% | ||
| Q3 25 | 0.5% | 16.1% | ||
| Q2 25 | 1.8% | 12.4% | ||
| Q1 25 | 0.8% | 12.6% | ||
| Q4 24 | 1.0% | 5.7% | ||
| Q3 24 | 0.1% | 3.9% | ||
| Q2 24 | 0.3% | 1.4% |
| Q1 26 | — | — | ||
| Q4 25 | 7.38× | — | ||
| Q3 25 | 3.06× | — | ||
| Q2 25 | 5.61× | — | ||
| Q1 25 | 6.61× | — | ||
| Q4 24 | 4.82× | — | ||
| Q3 24 | 3.72× | — | ||
| Q2 24 | 3.05× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GSHD
| Renewal Royalty Fees (2) | $43.6M | 47% |
| Renewal Commissions (1) | $18.2M | 20% |
| Contingent Commissions (1) | $10.7M | 11% |
| New Business Royalty Fees (2) | $7.9M | 8% |
| New Business Commissions (1) | $7.5M | 8% |
| Other | $3.7M | 4% |
| Initial Franchise Fees (2) | $1.6M | 2% |
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
